Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-016888
Filing Date
2021-02-09
Accepted
2021-02-09 21:15:16
Documents
2
Period of Report
2021-02-09

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm214979-2_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm214979-2_3seq1.xml 3 2196
2 EXHIBIT 24 tm214979d2_ex24.htm EX-24 7774
  Complete submission text file 0001104659-21-016888.txt   11612
Mailing Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103
Business Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103 (267) 207-3606
Vallon Pharmaceuticals, Inc. (Issuer) CIK: 0001824293 (see all company filings)

EIN.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address SANKT-JACOBS-STRASSE 90 CH-9002 BASEL V8 4052
Business Address SANKT-JACOBS-STRASSE 90 CH-9002 BASEL V8 4052 61 3137965
SALMON Pharma GmbH (Reporting) CIK: 0001843677 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-40034 | Film No.: 21608855